Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LY3023414 + LY3039478 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LY3023414 | Samotolisib|LY-3023414|LY 3023414 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | Samotolisib (LY3023414) is an ATP competitive inhibitor of PI3K/mTOR, inhibits signaling of the PI3K/mTOR pathway, and has demonstrated antiproliferative activity against tumor cells (PMID: 24387334, PMID: 31880826). | |
| LY3039478 | Crenigacestat|LY-3039478|JSMD194 | NOTCH Inhibitor (Pan) 5 | Crenigacestat (LY3039478) is a pan-NOTCH inhibitor, which may limit growth and survival of cancer cells (Cancer Res April 15, 2013 73; 1131, PMID: 32042099). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Terminated | USA | FRA | ESP | DNK | 0 |